2016
MPTH-01. ARE MUTATIONS IN MISMATCH REPAIR (MMR) GENES OUR NEXT BIOMARKER OF ALKYLATING AGENT INDUCED HYPERMUTATOR PHENOTYPE? PRELIMINARY RESULTS FROM THE IVY PRECISION TRIAL
Kuhn J, Chen R, Clarke J, Chang S, Cloughesy T, Colman H, Wen P, Mellinghoff I, Ligon K, de Groot J, Batchelor T, Omuro A, Taylor J, Butowski N, Halperin R, Tran N, Carpten J, Craig D, Byron S, Berens M, Prados M. MPTH-01. ARE MUTATIONS IN MISMATCH REPAIR (MMR) GENES OUR NEXT BIOMARKER OF ALKYLATING AGENT INDUCED HYPERMUTATOR PHENOTYPE? PRELIMINARY RESULTS FROM THE IVY PRECISION TRIAL. Neuro-Oncology 2016, 18: vi105-vi105. DOI: 10.1093/neuonc/now212.440.Peer-Reviewed Original ResearchIDH1 mutationMMR mutationsPRECISION trialHypermutator phenotypeMutation/lossClinical Trials ConsortiumHigh neoantigen loadRecurrent GBM tumorsWhole-exome sequencingMMR alterationsNext biomarkersPrior therapySpecific immunotherapyNeoantigen loadRecurrent GBMPhenotype patientsTumor boardMutational loadPatientsProgressive gliomasMGMT statusMLH1 mutationsGBM tumorsTherapeutic opportunitiesTumors
2005
Salvage temozolomide for prior temozolomide responders
Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer 2005, 104: 2473-2476. PMID: 16270316, DOI: 10.1002/cncr.21564.Peer-Reviewed Original ResearchConceptsDisease recurrenceRecurrent/progressive gliomaInitial disease recurrencePotential hematologic complicationsSubsequent salvage therapyFirst-line therapyProgression-free survivalTime of diagnosisLow-grade oligodendrogliomasWarrants further investigationSalvage therapyStable diseaseHematologic complicationsObjective responseRadiographic responseMedian ageRetrospective reviewDisease progressionTMZ treatmentAnaplastic astrocytomaPatientsProgressive gliomasRecurrenceTemozolomideSame agents